drugset
drugset / Trial / NCT01702896

Interleukin-2 in Metastatic Melanoma

NCT01702896 ↗

Phase 2 Terminated 8 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage

Timeline

Start
2012-09
Primary completion
2014-12
Completion
2014-12

Outcome

Outcome not reported

Stopped: “PI Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — —

Indications

metastatic melanoma